Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of advanced-stage nonsquamousnon-small cell lung cancer (NSCLC).

• Participants who have adverse events (AEs) due to previous anticancer therapies musthave recovered to Grade <1 or baseline.

• Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible ifthey have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeksand have undetectable HBV viral load.

• Participants with history of Hepatitis C virus (HCV) infection are eligible if HCVviral load is undetectable.

• Human immunodeficiency virus (HIV)-infected participants must have well controlledHIV on antiretroviral therapy.

• Life expectancy of at least 3 months.

Exclusion Criteria:

• Predominantly squamous cell histology NSCLC.

• History of second malignancy, unless potentially curative treatment has beencompleted with no evidence of malignancy for 3 years.

• Grade >2 peripheral neuropathy.

• History of documented severe dry eye syndrome, severe Meibomian gland disease and/orblepharitis, or corneal disease that prevents/delays corneal healing.

• Active inflammatory bowel disease requiring immunosuppressive medication or previoushistory of inflammatory bowel disease.

• Uncontrolled, or significant cardiovascular disease or cerebrovascular disease.

• Received prior radiotherapy within 2 weeks of start of study intervention, orradiation-related toxicities, requiring corticosteroids.

• Received a live or live-attenuated vaccine within 30 days before the first dose ofstudy intervention. Administration of killed vaccines is allowed.

• Received radiation therapy to the lung that is >30 Gray within 6 months of the firstdose of study intervention.

• Known active central nervous system metastases and/or carcinomatous meningitis.

• Active infection requiring systemic therapy.

• History of (noninfectious) pneumonitis/interstitial lung disease that requiredsteroids or has current pneumonitis/interstitial lung disease.

• HIV-infected participants with a history of Kaposi's sarcoma and/or MulticentricCastleman's Disease.

• Concurrent active HBV and HCV infection.

• History of allogeneic tissue/solid organ transplant.

• Participants who have not adequately recovered from major surgery or have ongoingsurgical complications.